Insulin Therapy

Overview

Insulin therapy is a hormone-replacement treatment in which exogenous insulin is administered to lower and stabilize blood glucose in people whose endogenous insulin secretion or action is insufficient. In clinical use since the early 1920s, it is the indispensable, lifelong treatment for type 1 diabetes, where autoimmune destruction of pancreatic beta cells abolishes endogenous secretion, and it is added in advanced type 2 diabetes when lifestyle measures, metformin, SGLT2 inhibitors, GLP-1 receptor agonists such as semaglutide, and other non-insulin agents no longer maintain adequate glycemic control. It is also used to manage drug-induced hyperglycemia, including the hyperglycemia caused by PI3K inhibitors such as alpelisib in oncology. Because the therapeutic goal is to reproduce a physiological secretion pattern, formulations are grouped by kinetics: rapid-acting analogs given as mealtime boluses or delivered by pump, and intermediate- or long-acting basal preparations. Dosing is titrated against glycemic monitoring, and the main treatment-limiting harm is hypoglycemia, alongside weight gain.

Therapeutically administered insulin acts through the same pathway as the native hormone, binding the insulin receptor — a receptor tyrosine kinase — and initiating signaling that drives glucose uptake into skeletal muscle and adipose tissue, suppresses hepatic glucose production, and promotes glycogen, lipid, and protein synthesis. In obesity-related type 2 diabetes this signaling is blunted by insulin resistance, characterized by reduced insulin-stimulated glucose uptake, intramuscular triacylglycerol accumulation, and mitochondrial dysfunction; resistance interacts with adipose-derived signals such as leptin and with cellular energy sensing through AMP-activated protein kinase, and progression to overt diabetes depends on whether beta-cell secretory compensation keeps pace with falling sensitivity. insulin signaling also has non-metabolic consequences: it shapes CD4+ effector memory T-cell metabolism and phenotype through epigenetic mechanisms, a link observed in autoimmune settings such as rheumatoid arthritis, and hyperinsulinemia is associated with an altered inflammatory milieu including interleukin-6 and C-C motif chemokine ligand 2. Current pharmaceutical development focuses on automated (closed-loop) insulin delivery systems paired with continuous glucose monitoring, on formulation stability and oligomerization behavior, which govern absorption kinetics, and on alternative routes — oral, sublingual, transdermal, and ocular — together with glucose-responsive delivery systems intended to release insulin in proportion to ambient glucose.

Recent Publications Summary (latest 30 papers)

Recent publications on insulin therapy focused heavily on delivery innovations, formulation stability, and glucose-responsive release systems. In type 1 diabetes, automated insulin delivery systems were evaluated for their potential budget impact versus standard multiple daily injections with intermittently scanned continuous glucose monitoring, with the analysis framed around improved glycemic control and reduced complication rates across nine European countries 42381171Jul. Several studies explored alternative delivery platforms, including pH-responsive injectable hydrogels for sustained insulin release, glucose-responsive G-quartet/protein hydrogels that promoted week-long normoglycemia in diabetic rats, and self-healing hydrogels for combined insulin and taurine delivery in diabetic wound healing 42148601May41979077Apr41943357Apr. Other work examined needle-free or minimally invasive approaches such as microfluidic jet injections into human ex vivo skin, separable bubble microneedles for transdermal and sublingual delivery, and plasma-activated pectin nanoparticles for oral insulin delivery 42009147AprPMID 4181867841713981Feb.

A second cluster of studies addressed insulin formulation behavior and aggregation. Dynamic light scattering was used to build a rapid hydrodynamic molecular weight model for assessing oligomerization states of therapeutic proteins, including insulin analogs, with observed oligomerization largely consistent with literature reports 42373916Jun. Related work showed that supramolecular chaperone-like dendrons could prevent insulin aggregation for multiple days under chemical and mechanical stress, highlighting a potential strategy to improve protein stability 41988752Apr. Long-term stability testing of insulin eye drops found that formulations prepared in normal saline or artificial tears remained stable for at least 60 days under refrigerated storage, whereas a commercial eye-drop vehicle showed turbidity and reduced suitability 41997424Apr. These studies collectively underscore ongoing efforts to improve insulin stability, handling, and nontraditional routes of administration 42373916Jun41988752Apr41997424Apr.

Several publications examined insulin in clinical and physiological contexts beyond direct replacement therapy. In type 2 diabetes, a randomized protocol was published for the COYOTE study comparing fully closed-loop insulin delivery with standard insulin therapy plus CGM 42156154May. Observational work reported on quality of life among insulin-treated type 2 diabetes patients in tertiary care hospitals, while another real-world cohort in Hispanic adults found that insulin use was associated with poorer glycemic control compared with some non-insulin regimens 42047131Apr41987878Apr. In gestational diabetes, a parsimonious LASSO model and point-based risk score were developed to predict insulin requirement 41912039Mar. insulin use was also examined as a marker of diabetes severity in acute ischemic stroke patients undergoing mechanical thrombectomy, where long-term insulin treatment status was associated with worse adjusted outcomes in the matched cohort 42156589May. In alpelisib-treated breast cancer patients, insulin was among the antidiabetic agents commonly used to manage treatment-induced hyperglycemia 42159385May.

Mechanistic studies further expanded understanding of insulin biology. In obese male mice, vagal activation altered insulin dynamics through neuronal nitric oxide synthase-dependent signaling, with obesity enhancing the insulin-decreasing effect of vagal stimulation 42189938May. In skeletal muscle from obese and type 2 diabetes participants, markers of the unfolded protein response were not elevated, and insulin infusion altered some UPR-related transcripts without major group differences 42017540Apr. In rheumatoid arthritis tissues, insulin signaling supported acquisition of an IL7R+ memory phenotype in PD1+ T cells and interacted with histone acetylation pathways 42185247May. Additional studies linked postprandial insulin dynamics to heterogeneity in obesity, identified 1-hour plasma glucose as a marker of early-phase insulin secretory defects in young adults with obesity, and explored how amino acid combinations modulate insulin secretion from human islets 42166654May42184890May42017410Apr.

What Changes, What Holds

1. Delivery is moving toward automated and noninvasive systems, but the core therapeutic role is unchanged -- NEW DIRECTION -- Automated delivery and several alternative platforms broaden how insulin can be administered, yet they do not alter the baseline account that it is used to replace insufficient endogenous hormone and to improve glycemic control. The budget-impact analysis for closed-loop systems mainly strengthens the case for wider implementation, while the hydrogel, microneedle, jet-injection, and oral approaches point to future routes that may reduce burden or improve adherence rather than redefine the treatment itself 42381171Jul42009147Apr.

2. Stability engineering is becoming central to making insulin usable in new formats -- METHOD -- Work on oligomerization modeling and chaperone-like protection changes how insulin is characterized and stabilized, not what it does clinically. The eye-drop stability data and aggregation-prevention findings matter because they support nontraditional formulations and longer handling windows, but they leave the established pharmacology intact. What is new here is the emphasis on measuring and controlling molecular state as a prerequisite for delivery, especially for routes where aggregation or turbidity would otherwise limit feasibility 42373916Jun41988752Apr.

3. insulin is being used as a marker of disease severity and treatment burden in more settings, not just as replacement therapy -- NEW DIRECTION -- Observational and protocol-level studies extend insulin beyond the baseline’s replacement and hyperglycemia-management roles by treating it as a prognostic or stratifying variable in type 2 diabetes, gestational diabetes, stroke, and alpelisib-associated hyperglycemia. That does not contradict its established use, but it does add a second layer: insulin requirement or long-term use may index more advanced metabolic disease and worse outcomes in some cohorts. The evidence is associative and context-specific, so it should be read as hypothesis-generating rather than practice-changing 42047131Apr42156589May.

4. Neural and immune context continues to reshape how insulin signaling is understood, but not its basic metabolic mechanism -- REINFORCES -- The new mechanistic studies fit the baseline’s view that insulin signaling has non-metabolic consequences in immune cells and is modulated by systemic physiology. Vagal control of insulin dynamics, transcript-level responses in muscle, and T-cell epigenetic effects all sharpen the picture of how obesity, neural input, and inflammation intersect with insulin biology. None of these findings displace the established receptor-mediated metabolic actions; they extend the network around them and help explain why insulin responses vary across tissues and disease states 42189938May42185247May.

Overview update candidates: automated and noninvasive delivery platforms; stability/aggregation control as a key enabling issue; insulin requirement or long-term use as a severity marker in some clinical settings.